INDEMNITY AGREEMENTIndemnity Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • Delaware
This Indemnity Agreement, dated as of [ ], 2021 is made by and between Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ], a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. OYSTER POINT MARINA PLAZA OFFICE LEASE of SUITE 217 to DAY...Office Lease • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • California
THIS OFFICE LEASE (the “Lease”) is entered into as of February 8, 2020, by and between KASHIWA FUDOSAN AMERICA, INC., a California corporation (“Landlord”) and DAY ONE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
DAY ONE BIOPHARMACEUTICALS HOLDING COMPANY, LLC AMENDED AND RESTATED OPERATING AGREEMENT DATED AS OF FEBRUARY 1, 2021Operating Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • Delaware
This Amended and Restated Operating Agreement, dated as of February 1, 2021 (this “Agreement”), is by and among Day One Biopharmaceuticals Holding Company, LLC, a Delaware limited liability company (the “LLC”) and the persons identified as the Members on Schedule A attached hereto (such persons and their respective successors and permitted assigns being hereinafter referred to individually as a “Member” or collectively as the “Members”), as such Schedule A may hereinafter be amended.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. LICENSE AGREEMENT dated February 10, 2021 by and between...License Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations
WHEREAS, MRKDG is engaged, among other activities, in the development of pharmaceutical products and is the holder of several rights in the Compounds (as defined below);
ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • Delaware
This Asset Transfer and License Agreement (“Agreement”) is made effective as of December 16, 2019 (the “Effective Date”) by and between DOT THERAPEUTICS-1, INC. (“Day One”), a Delaware corporation and an Affiliate of Day One Holdings, LLC, having a place of business at 2765 Sand Hill Road, Menlo Park, CA 94025, and MILLENNIUM PHARMACEUTICALS, INC. (“Takeda”), a Delaware corporation and an Affiliate of Takeda Pharmaceutical Company Limited, having a place of business at 40 Landsdowne Street, Cambridge, MA 02139.
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • Delaware
This Share Exchange Agreement (this “Agreement”) is made and entered into as of May 4, 2021 (the “Agreement Date”), by and among (a) Day One Biopharmaceuticals Holding Company, LLC, a Delaware limited liability company (the “Company”), (b) DOT-1 Therapeutics, Inc., a Delaware corporation (“Subsidiary”) and (c) Millennium Pharmaceuticals, Inc. (the “Stockholder”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. LICENSE AGREEMENT FOR RAFLicense Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • Delaware
This LICENSE AGREEMENT FOR RAF (the “Agreement”), effective as of December 16, 2019 (the “Effective Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (“Sunesis”), and DOT Therapeutics-1, Inc., a Delaware corporation, having a principal place of business at 2765 Sand Hill Road, Menlo Park, CA 94025 (“DOT-1”). Sunesis and DOT-1 are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
